lncRNA MIAT targets miR‐411‐5p/STAT3/PD‐L1 axis mediating hepatocellular carcinoma immune response-Reference-Cited by-同舟云学术

lncRNA MIAT targets miR‐411‐5p/STAT3/PD‐L1 axis mediating hepatocellular carcinoma immune response

Published:2022-04-15 Issue:3 Volume:103 Page:102-111
ISSN:0959-9673
Container-title:International Journal of Experimental Pathology
language:en
Short-container-title:Int J Experimental Path

Author:

Zhang Xiaoxia¹,Pan Banglun¹,Qiu Jiacheng¹,Ke Xiaoling¹,Shen Shuling¹,Wang Xiaoqian¹,Tang Nanhong¹²^ORCID

Affiliation:

1. Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery Cancer Center of Fujian Medical UniversityFujian Medical University Union Hospital Fuzhou China

2. Key Laboratory of Ministry of Education for Gastrointestinal Cancer Research Center for Molecular Medicine Fujian Medical University Fuzhou China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iep.12440

Reference37 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

2. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

3. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

4. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma

5. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA-411-5p alleviates lipid deposition in metabolic dysfunction-associated steatotic liver disease by targeting the EIF4G2/FOXO3 axis;Cellular and Molecular Life Sciences;2024-09-11

2. Puzzling out the role of MIAT LncRNA in hepatocellular carcinoma;Non-coding RNA Research;2024-06

3. The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma;Discover Oncology;2024-05-07

4. RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials;European Journal of Pharmaceutics and Biopharmaceutics;2024-04

5. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways;Cancer Cell International;2024-03-10